HYDERABAD: Vaccine maker Biological E (BE) on Tuesday said its Covid vaccine Corbevax has received emergency use listing (EUL) from the WHO.
Corbevax, which was India’s first indigenously developed Covid- vaccine based on the protein sub-unit platform, was approved in India for restricted use. While the DCGI granted emergency use authorisation for Corbevax in adults, adolescents and young children from December 2021 to April 2022, it also gave its nod for using the vaccine as a heterologous booster in those aged 18 years and above in June 2022.
The Hyderabad-based vaccine maker has already supplied 100 million doses of Corbevax to the Indian government for pan-India immunisation campaigns.The vaccine was primarily utilised in vaccinating children in the 12-14 age group.
“Our commitment is to provide affordable and accessible vaccines that are of high quality and the WHO EUL lays a path for us to make that possible,” Biological E managing director Mahima Datla said.
Corbevax, which was India’s first indigenously developed Covid- vaccine based on the protein sub-unit platform, was approved in India for restricted use. While the DCGI granted emergency use authorisation for Corbevax in adults, adolescents and young children from December 2021 to April 2022, it also gave its nod for using the vaccine as a heterologous booster in those aged 18 years and above in June 2022.
The Hyderabad-based vaccine maker has already supplied 100 million doses of Corbevax to the Indian government for pan-India immunisation campaigns.The vaccine was primarily utilised in vaccinating children in the 12-14 age group.
“Our commitment is to provide affordable and accessible vaccines that are of high quality and the WHO EUL lays a path for us to make that possible,” Biological E managing director Mahima Datla said.
